In summary, our study reveals a novel mechanism by which polydatin targets both WT and mutant NLRP3 through HSP90α inhibition, offering a potential therapeutic approach for CAPS and other NLRP3-related disorders. Here, HSP90AA1 is linked to cryopyrin-associated periodic syndrome.